PTJ
VIR icon

Paul Tudor Jones’s Vir Biotechnology VIR Stock Holding History

Paul Tudor Jones’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-73,504
Closed -$659K – 4329
2026
Q1 		$659K Buy
73,504
+4,930
+7% +$39.3K ﹤0.01% 2646
2025
Q4 		$414K Buy
+68,574
New +$408K ﹤0.01% 2824
2025
Q2 		– Sell
-68,349
Closed -$443K – 3796
2025
Q1 		$443K Buy
+68,349
New +$608K ﹤0.01% 2351
2024
Q4 		– Sell
-68,113
Closed -$510K – 3542
2024
Q3 		$510K Buy
68,113
+209
+0.3% +$1.81K ﹤0.01% 2022
2024
Q2 		$604K Buy
67,904
+3,089
+5% +$29.6K ﹤0.01% 1720
2024
Q1 		$657K Buy
+64,815
New +$660K ﹤0.01% 1526
2023
Q4 		– Sell
-67,202
Closed -$630K – 2941
2023
Q3 		$630K Buy
+67,202
New +$958K 0.01% 1559

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Paul Tudor Jones's VIR Position: Q2 2026 in Review

Paul Tudor Jones sold out of Vir Biotechnology (VIR) in Q2 2026, closing a stake of 73,504 shares — an estimated $659K sold.

Paul Tudor Jones first reported a position in VIR in Q3 2023 and held it in 7 quarters. The position peaked at $659K in Q1 2026. 236 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Paul Tudor Jones reported no remaining Vir Biotechnology position as of Q2 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 73,504 Vir Biotechnology shares in Q2 2026, an estimated $659K.
  • Paul Tudor Jones first reported a position in Vir Biotechnology in Q3 2023 and held it in 7 quarters.
  • Paul Tudor Jones's Vir Biotechnology position peaked at $659K in Q1 2026.
  • 236 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.